Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults (≥18yrs) in asthma

Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients down ¹. The decision to step-down/ up therapy should be jointly made between the clinician and the patient. Table 1 defines the levels of asthma control. When stepping patients down/ up or switching therapy, prescribers should keep device changes to a minimum and consider the cost and beclometasone dipropionate (BDP) equivalence of different inhaler devices ^{1, 2}. Table 2 shows the cost comparison between different inhaler types used in asthma. Table 3 demonstrates the variation in BDP equivalence across different corticosteroids.

Key principles:

- The BTS/SIGN guidance ¹ on the stepwise management of asthma should be used to treat patients at the step most appropriate to the initial severity of their asthma
- When reviewing asthma therapy, compliance, inhaler technique and trigger factors should be checked by practitioners
- Inhaled corticosteroids (ICS) are safe and effective for most patients with asthma, although the risk of systemic side effects is greater when higher doses are used. The dose of ICS should be titrated to the lowest dose at which effective asthma control is maintained ³
- If asthma is controlled with a combination ICS/long-acting beta2 agonist (LABA) inhaler, the preferred approach is to reduce the ICS by approximately 25-50% whilst continuing the LABA at the same dose.^{1, 2}
- The decision to use a combination device or the two agents in separate devices should be made on an individual basis, taking into consideration therapeutic need and the likelihood of treatment adherence ⁴
- If control is maintained after stepping-down, further reductions in the ICS should be attempted until a low dose is reached, when the LABA may be stopped²
- Appendix 1 contains a copy of the Asthma UK patient self-management plan which should be completed for all patients with asthma. <u>Click here to obtain an editable electronic copy of</u> <u>the Asthma UK patient self-management plan</u> (link)

Та	Table 1: LEVELS OF ASTHMA CONTROL ²					
Assessmer	nt of current clinical control (pr	ref	erably over 4 weeks)			
Characteristic	Completely Controlled		Partly Controlled	Uncontrolled		
Daytime symptoms	None (twice or less/week)		>Twice/week			
Limitation on activities	None		Any			
Nocturnal symptoms/awakening	None		Any	Three or more features of partly		
Need for reliever/rescue treatment	None (twice or less/week)		>Twice/week	controlled asthma		
Lung function (PEF or FEV_1)	Normal	I	<80% predicted or personal best (if known)			

Page 1

BTS/SIGN Summary of stepwise asthma management in adults ¹ (reproduced)

Patients should start treatment at the step most appropriate to the initial severity of their asthma. Check concordance and reconsider diagnosis if response to treatment is unexpectedly poor.

Move up to improve control as needed



Step 1	Step 1 Step 2	Step 3	Step 4	Step 5
Salbutamol Inhaler (<i>M</i>) 100mcg 2 puffs prn £0.45 **Easyhaler Salbutamol (<i>D</i>) 100mcg 2 puffs prn £0.99 Salbutamol Accuhaler (<i>D</i>) 200mcg 1 puff prn £1.50 Salbutamol Autohaler (<i>B</i>) 100mcg 2 puffs prn £1.89 Terbutaline Turbohaler (<i>D</i>) 500mcg 1 puff prn £2.08 (<i>M</i>) – Metered Dose Inhaler (Use with a suitable spacer device) (<i>D</i>) – Dry Powder Inhaler; (<i>B</i>) – Breath Actuated ** Must be prescribed by brand	400-500mcg BDP equiv./dnol Inhaler (M)puffs prn £0.45© Salbutamolncg 2 puffs prn£0.99I Accuhaler (D)puff prn £1.50ol Autohaler (B)puffs prn £1.89Turbohaler (D)puff prn £2.08Part Clenil Modulite Inhaler (M)Somcg 2 puffs bd £4.45**Qvar Easi-Breathe (B)50mcg 2 puffs bd £4.65**Qvar Inhaler (M)50mcg 2 puffs bd £4.72**Easyhaler Budesonide (B)puffs prn £1.89* Turbohaler (D)puff prn £2.08Puff prn £2.08red Dose Inhalerowder Inhaler;n Actuatedprescribed by	 LABA can be added to an inhale Where a LABA is added 400-500mcg BDP equiv./day: Flutiform 125/5 Inhaler (M) 1 puff bd £14.63 Fostair 100/6 Inhaler (M) 1 puff bd £14.66 Flutiform 50/5 Inhaler (M) 2 puffs bd £18.00 Seretide 100 Accuhaler (D) 1 puff bd £18.00 Seretide 50 Evohaler (M) 2 puffs bd £18.00 Symbicort 200/6 Turbohaler (D) 1 puff bd £19.00 Symbicort 100/6 Turbohaler (D) 2 puffs bd £33.00 800mcg BDP equiv./day: Symbicort 200/6 Turbohaler (D) 2 puffs bd £33.00 Symbicort 400/6 Turbohaler (D) 1 puff bd £38.00 	d steroid either in a combination separately **Easyhaler Formon 1000mcg BDP equiv./day: Flutiform 250/10 Inhaler (M) 1 puff bd £22.78 Flutiform 125/5 Inhaler (M) 2 puffs bd £29.26 Fostair 100/6 inhaler (M) 2 puffs bd £29.32 Seretide 250 Accuhaler (D) 1 puff bd £35.00 Seretide 125 Evohaler (M) 2 puffs bd £35.00 1600mcg BDP equiv./day: Symbicort 400/6 Turbohaler (D) 2 puffs bd £76.00	2000mcg BDP equiv./day: Seretide 500 Accut (D) 1 puff bd £40. Flutiform 250/10 In (M) 2 puffs bd £45 Seretide 250 Evoh (M) 2 puffs bd £59 Adding in daily ste tablet and maintai patient at 2000mcg equiv./day takes pa to Step 5
Maintenance and Reliever TherapySMAFostair MART 100/6 Inhaler (M) 1 puff bd + 1 puff prn (max. 8 puffs/day) $\pounds 21.99$ Symbicort SMART 200/6 Turbohaler (D) 1-2 puffs bd + 1 puff prn (max. 8 puffs/day) $\pounds 28.50/ \pounds 47.50$ (\neq Prices based upon standard dose + 1 extra puff/day) should be added by the standard dose + 1 extra puff/day)SMA Patie and comparison of the standard dose + 1 extra puff/day)		 ART®/MART® can be considered for patients with: Inadequate asthma control and a frequent need of reliever medication Asthma exacerbations in the past requiring medical intervention ents must have received education on the use of the inhaler as maintenance and reliever the clinicians must be confident patients understand how to use it appropriately. Patients should ised to always have their inhaler available for rescue use. Patients requiring frequent use of cue inhalations daily should be advised to return to the GP practice for reassessment. Practicul monitor the number of prescriptions requested and any dose-related adverse effects. 		

Table 3: Variations	Beclometasone			
Inhaled Corticosteroid	Brand	Type of inhaler	Dose	equivalent daily dose
	Clenil [®]	Metered dose Inhaler	100mcg 2 puffs twice a day	400mcg
Beclometasone	Easyhaler [®]	Dry Powder Inhaler	200mcg 1 puff twice a day	400mcg
	Qvar [®]	Metered dose Inhaler	50mcg 2 puffs twice a day	400mcg
	**Fostair [®]	Metered dose Inhaler	100mcg 1 puffs twice a day	500mcg
	Easyhaler [®]	Dry Powder Inhaler	200mcg 1 puff twice a day	400mcg
Budesonide	Pulmicort [®]	Dry Powder Inhaler	200mcg 1 puff twice a day	400mcg
	**Symbicort [®]	Dry Powder Inhaler	200mcg 1 puff twice a day	400mcg
	Flixotide [®]	Dry Powder Inhaler	100mcg 1 puff twice a day	400mcg
Fluticasone	**Flutiform [®]	Metered dose Inhaler	125mcg 1 puff twice a day	500mcg
	**Seretide [®]	Metered dose Inhaler	125mcg 1 puff twice a day	500mcg

** These products are inhaled corticosteroid and long-acting β₂ agonist (LABA) combination inhalers

NB. The dose equivalences for ciclesonide and mometasone are not well established

References

- 1. British Thoracic Society. Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Revised January 2012. http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf
- 2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2012 update http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf
- 3. NPC MeReC Bulletin 2008; Vol. 19 no.2
- 4. National Institute for Health and Clinical Excellence. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over. NICE technology appraisal guidance 138. 2008 Mar. <u>http://www.nice.org.uk/TA138</u>
- 5. Adapted from MeReC Bulletin 2008;13(2) & BTS/SIGN Asthma Guidance 2012

Acknowledgement to Jenny Gibbs, Medicines Management Team, Bristol CCG for baseline layout

Instructions: How to step patients down

Ascertain whether the patient has achieved complete asthma control for at least 3 months (see Table 1 on page 1).

Step the patient down

 Using table 2 (page 3), identify the combination inhaler and dose the patient is currently being prescribed. Identify which step (2-5) this product and dose represents

Yes

- Consider using the most appropriate cost effective product when stepping down patients (see table 2)
- 3. Refer to pages 6 to 9 when stepping down using the same combination products
- It may be more cost effective to change products during step down. If appropriate, prescribe the dose suitable to that step and ensure that the patient is shown how to use any potentially new device

Note for patients at steps 4 & 5: If the patient is prescribed add-on therapies (e.g. montelukast, oral prednisolone) consider reducing/stopping these one by one before attempting to reduce



Has the patient achieved complete asthma control in the last 3 months (see Table 1)?

(*If you previously stepped the patient up to cover the hay fever season and wish to step them down again, review the patient in 1 month rather than 3 months).



Step the patient down again and repeat cycle

Do not step the patient down

- 1. Check inhaler technique
- 2. Check exposure to trigger factors
- 3. Check adherence to therapy and consider any issues which may affect compliance

No

If these have been excluded, step-up therapy

Clinicians should consider:

Patients achieve complete asthma control at different rates. Clinicians should have a discussion with the patient to decide whether to trial the current therapy for longer or to step-up again.

Suggested discussion points with patient:

- 1. Are there any factors affecting adherence to therapy e.g. polypharmacy, social reasons or beliefs?
- 2. Are there any issues affecting compliance e.g. dexterity?
- 3. Is the patient exposed to trigger factors e.g. smoking, pets, pollen or stress?
- 4. Are there any lifestyle points to consider where asthma stability is crucial e.g. impending exam
- 5. How long did it take the patient to achieve complete asthma control last time?
- 6. What would be the potential consequences of an exacerbation and does the patient know what to do if this occurs?
- 7. What would the patient prefer to do?
- 8. Ensure the patient has an up to date self-management plan

Action:

Clinicians should use their professional judgement to decide whether to continue trialling the current therapy, or to step-up again. If continuing on the current therapy for longer, the clinician should advise the patient to monitor their symptoms and short-acting bronchodilator use, and review the patient again in 1 month. Patients should be advised to follow their self-management plan if their symptoms become problematic within this time.

Refer to a specialist if necessary.

Page 5 Approved by BHR Area Prescribing Sub-Committees Nov 13. Review Nov 2015

No









Approved by BHR Area Prescribing Sub-Committees Nov 13. Review Nov 2015

Appendix1

Asthma UK Patient Self-Management Plan

your asthma action plan



- The Asthma UK patient self-management plan should be completed for all patients with asthma
- Copies of the Asthma UK patient self-management plan can be ordered by emailing info@asthma.org.uk or calling Asthma UK's Supporter Care Team on 0800 121 62 55
- <u>Click here to obtain an editable electronic copy of the Asthma UK patient self-</u> <u>management plan</u> (link)
- The editable electronic copy of the Asthma UK patient self-management plan is available on each CCG's prescribing guidance webpage:

Barking and Dagenham (link) Havering (link) Redbridge (link)

This is what I need to do to stay on top of my asthma:	My asthma is getting worse if I notice any of these:	I am having an asthma attack if any of these happen:
My personal best peak flow is:	 My symptoms are coming back (wheeze, tightness in my chest, feeling breathless, cough) I am waking up at night My symptoms are interfering with my usual day-to-day activities (eg at work, exercise) I am using my reliever inhaler times a week or more My peak flow drops to below 	My reliever inhaler is not helping or I need it more than every hours I find it difficult to walk or talk I find it difficult to breathe I'm wheezing a lot or I have a very tight chest or I'm coughing a lot My peak flow is below
My reliever inhaler (insert name/colour) I take my reliever inhaler only if I need to. I take puff(s) of my reliever inhaler if any of these things happen: I'm wheezing My chest feels tight I'm finding it hard to breathe I'm coughing	This is what I can do straight away to get on top of my asthma: 1 If I haven't been using my preventer inhaler, start using it regularly again or: Increase my preventer inhaler dose to until my symptoms have gone and my peak flow is back to normal. Take my reliever inhaler as needed (up to	 THIS IS AN EMERGENCY TAKE ACTION NOW Take two puffs of my reliever inhaler (one puff at a time) Sit up and try to take slow, steady breaths If I don't start to feel better, take two puffs of my reliever inhaler (one puff at a time) every two minutes. Loan take up to ten puffs
Other medicines I take for my asthma every day: Contact number for GP/specialist asthma nurse:	puffs every four hours). If I don't improve within 48 hours make an appointment to see my GP or asthma nurse. 2 If I have been given prednisolone tablets (steroid tablets) to keep at home: Take mg of prednisolone tablets	 If I don't feel better I should call 999 straight away. If an ambulance doesn't arrive within ten minutes, and I'm still not feeling better, then I should repeat Step 3 Even if I feel better after this I should see my GP or asthma nurse for advice the same day
When you have good control over your asthma you should have no symptoms. If you have hay fever or a food allergy it's even more important to have good control of your asthma.	(which is x 5mg) immediately and again every morning for days or until I am fully better. Call my GP today and let them know I have started taking steroids and make an appointment to be seen within 24 hours.	6 If I have rescue prednisolone tablets, take 40mg (8 x 5mg) altogether Please note this asthma attack information is not designed for people who use the Symbicort SMART regime. If you use Symbicort SMART please speak to your GP or asthma nurse about this.

Page 10 Approved by BHR Area Prescribing Sub-Committees Nov 13.